Tocilizumab is not recommended for ICANS due to its potential to elevate IL-6 levels in the cerebrospinal fluid (CSF), potentially worsening ICANS [6] Although tocilizumab can significantly alleviate CRS, patients may still progress to CAR-T cell-related HLH. This evidence concerns the gene IL6 and congenital rubella syndrome.